case study

Strategy for Pharmaceutical Submission

A major manufacturer of IV pharmaceuticals was facing leakage problems with the IV bag. RCA suggested a CBE 30, which they submitted to the FDA, addressing product complaints and maintaining product revenue.

About RCA
Regulatory Compliance Associates® Inc. (RCA) provides worldwide services to the pharmaceutical, biologic, sterile compounding, biotechnology, and medical device industries for resolution of compliance and regulatory challenges.

Please complete the form to access the case study.

*=Required

Strategy for Pharmaceutical Submission

Background

A major manufacturer of IV pharmaceuticals was facing leakage problems with the IV bag. Their quality and engineering teams identified a solution that would eliminate the leaks by making a change to the resins in the bag. They were unclear on the submission strategy since the guidance documents were unclear, so the company was defaulting to a time-intensive Prior Approval Supplement (PAS).

RCA saved about 1 ½ years from the schedule, maintaining revenues and increasing product quality.

Solution

The Regulatory Compliance Associates® Inc. consultant examined the corrective action, noting that the strengthening of the IV bag came from changing the ratio of the resins but not the actual resins. Because no new resins were being introduced to the pharmaceutical, RCA suggested a CBE 30 instead of the PAS.

Result

After reviewing the RCA strategy with the FDA, the company submitted the CBE 30 and was able to address product complaints and maintain product revenues.

Background

A major manufacturer of IV pharmaceuticals was facing leakage problems with the IV bag. Their quality and engineering teams identified a solution that would eliminate the leaks by making a change to the resins in the bag. They were unclear on the submission strategy since the guidance documents were unclear, so the company was defaulting to a time-intensive Prior Approval Supplement (PAS).

RCA saved about 1 ½ years from the schedule, maintaining revenues and increasing product quality.

Solution

The Regulatory Compliance Associates® Inc. consultant examined the corrective action, noting that the strengthening of the IV bag came from changing the ratio of the resins but not the actual resins. Because no new resins were being introduced to the pharmaceutical, RCA suggested a CBE 30 instead of the PAS.

Result

After reviewing the RCA strategy with the FDA, the company submitted the CBE 30 and was able to address product complaints and maintain product revenues.

Interested in Learning More?

Contact Us